Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

Diabetes Drug Ozempic Coming to India This Month

Novo Nordisk's semaglutide portfolio in India will be completed with the launch of Ozempic, providing therapeutic options for both diabetes and obesity. This introduction follows increasing competition from Eli Lilly's Mounjaro, a US rival approved for both diabetes and weight management. Pharmarack data indicates that Lilly sold 262,000 doses of Mounjaro in October, compared to Novo's Wegovy with 26,000 doses.

Novo Nordisk already maintains a significant presence in the diabetes market in India through its Rybelsus semaglutide tablets and other offerings. According to Vishal Manchanda, an analyst from Systematix Institutional Equities, "Novo is well-positioned to promote Ozempic due to its established brand recognition in diabetes treatment."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Furthermore, Manchanda suggested that "Ozempic may potentially be prescribed for individuals experiencing infertility or sleep apnea, and for those seeking weight reduction." Health tracking apps like Shotlee can help monitor any side effects from new medications.

Source Information

Originally published by NewsBytes.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read

Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read

Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Same topic: Diabetes

All Diabetes articles →

Health & Wellness

Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?

New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.

7 min read

Health & Wellness

Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think

Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.

6 min read

Health & Wellness

Beyond the Scale: Are GLP-1 Drugs Depleting Vital Nutrients?

While GLP-1 agonists are revolutionizing weight management, emerging research suggests a potential downside: nutrient deficiencies. This article delves into what the latest studies reveal about these vital nutrient gaps and how to address them.

6 min read

More in Health

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read